Drug Information

Drug (ID: DG01730) and It's Reported Resistant Information

Name	Cabozantinib/Erlotinib
Synonyms	Cabozantinib/Erlotinib Click to Show/Hide
Target	.	NOUNIPROTAC	[1]

Type(s) of Resistant Mechanism of This Drug

ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Lung cancer [ICD-11: 2C25]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)		Click to Show/Hide
Key Molecule: Epidermal growth factor receptor (EGFR)			[1]
Molecule Alteration	Missense mutation	p.T790M (c.2369C>T)	Molecule Info
Sensitive Disease	Lung adenocarcinoma [ICD-11: 2C25.0]		Disease Info
Experimental Note	Identified from the Human Clinical Data

References

Ref 1	Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)Front Oncol. 2019 Mar 11;9:132. doi: 10.3389/fonc.2019.00132. eCollection 2019.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.